Home > Cardiology > Lipoprotein(a) levels tied to atherosclerotic heart disease risk

Lipoprotein(a) levels tied to atherosclerotic heart disease risk


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Cardiology
Conference
European Atherosclerosis Society 2020
Reuters Health - 08/10/2020 - Higher levels of lipoprotein(a) and higher LPA genetic risk scores are associated with an increased risk of developing atherosclerotic cardiovascular disease (ASCVD), according to data from the U.K. "As genetic testing becomes increasingly commonplace, we anticipate there will be increased recognition of lipoprotein(a), since its corresponding risk information is fully captured by genetic testing," said Dr. Pradeep Natarajan of Massachusetts General Hospital, in Boston. "First-cardiovascular-disease-event risk prediction for lipoprotein(a), whether via genetics or direct measurement, appears most suitable for individuals at borderline or intermediate risk," told Reuters Health by email. "Both genetic information and direct measurement carry redundant risk-prediction information." The findings were published in JAMA Cardiology to coincide with a presentation October 6 at the European Atherosclerosis Society 2020 virtual conference...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on